Sanofi India Ltd — earnings calls
1 quarter summarised from transcripts filed with the exchange, every statement cited. Newest first.
Q1 FY27 earnings call
Sanofi India reported quarter two 2026 results with diabetes business growth of close to 14%, driven by Toujeo and Soliqua, while the partnership business with Emcure and Cipla grew 2% in the quarter. Profit before tax and exceptional items rose 19% year-on-year to INR 112 crores from INR 94 crores, with margin improving to 27% of net sales from 24%. Management discussed export market challenges in Australia offset partly by other markets, and noted cash balance grew 34%.